FDA calendar · March 2024 · built from SEC filings

PDUFA dates March 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

4 PDUFA dates fell in March 2024: LCTX (Mar 2024), HETLIOZ® (March 4), MDGL (March 14), RCKT (March 31). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in March 2024

4 PDUFA target action dates in March 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
Mar 2024Lineage Cell Therapeutics, Inc.LCTXNot namedsec_424b, filed 2024-11-21
March 4, 2024Vanda Pharmaceuticals Inc.VNDAHETLIOZ® (tasimelteon)SEC Form 10-K, filed 2025-02-14
March 14, 2024MADRIGAL PHARMACEUTICALS, INC.MDGLNot namedSEC Form 10-K, filed 2025-02-26
March 31, 2024ROCKET PHARMACEUTICALS, INC.RCKTNot namedSEC Form 10-Q, filed 2025-08-07

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

March 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Mar 2024Month disclosedImmCelzCELZFDA approvalBrittle Type 1 DiabetesApprovedsec_s1
Mar 2024Month disclosedXHANCEINSMFDA approval—ApprovedSEC 8-K Exhibit 99.1
March 1, 2024Rybrevant (amivantamab-vmjw)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
Mar 2024Month disclosedgenericMRKFDA approval—ApprovedSEC Form 10-K
Mar 2024Month disclosedTEVIMBRA® (tislelizumab)ONCFDA approval—ApprovedSEC Form 10-Q
Mar 2024Month disclosedOpillPRGOFDA approval—ApprovedSEC Form 10-K
March 4, 2024—VNDAComplete Response Letter—CRL issuedSEC Form 10-K
March 5, 2024Prolia® (denosumab)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
March 6, 2024Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 6, 2024Besponsa (inotuzumab ozogamicin)PFELabel expansion—ApprovedopenFDA Drugs@FDA
March 7, 2024BRUKINSA® (zanubrutinib)ONCLabel expansion—ApprovedopenFDA Drugs@FDA
March 7, 2024Talzenna (talazoparib tosylate)PFEFDA approval—ApprovedopenFDA Drugs@FDA
March 7, 2024Caprelsa (vandetanib)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
March 8, 2024Wegovy (semaglutide)NVOLabel expansion—ApprovedopenFDA Drugs@FDA
March 8, 2024Praluent (alirocumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
March 13, 2024LIVMARLI® (maralixibat)MIRMLabel expansion—ApprovedopenFDA Drugs@FDA
March 13, 2024Tevimbra (tislelizumab-jsgr)ONCFDA approvalTo treat unresectable or metastatic esophageal squamous cell carcinomaApprovedFDA Novel Drug Approvals
March 14, 2024RYTELO (imetelstat)GERNAdvisory committee—PositiveFDA advisory committee calendar
March 14, 2024Rezdiffra (resmetirom)MDGLFDA approvalwith noncirrhotic MASH with moderate to advanced liver fibrosisApprovedSEC 8-K Exhibit 99.1
March 15, 2024ABECMA (idecabtagene vicleucel)BMYAdvisory committee—PositiveFDA advisory committee calendar
March 15, 2024CARVYKTI (ciltacabtagene autoleucel)JNJAdvisory committee—PositiveFDA advisory committee calendar
March 15, 2024Edurant Ped (rilpivirine hydrochloride)JNJFDA approval—ApprovedopenFDA Drugs@FDA
March 15, 2024Edurant Ped (rilpivirine hydrochloride)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
March 19, 2024Iclusig (ponatinib hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2024Ultomiris (ravulizumab-cwvz)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2024Brilinta (ticagrelor)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2024Opsynvi (macitentan; tadalafil)JNJFDA approval—ApprovedopenFDA Drugs@FDA
March 22, 2024Ordspono™ (odronextamab)REGNComplete Response Letterrelapsed/refractory FL and DLBCL dueCRL issuedSEC Form 10-Q
March 26, 2024Winrevair (sotatercept-csrk)MRKFDA approvalTo treat pulmonary arterial hypertensionApprovedFDA Novel Drug Approvals
March 27, 2024Vafseo® (vadadustat)AKBANDA/BLA submission—CompletedSEC Form 10-Q
March 27, 2024Vafseo® (vadadustat)AKBAFDA approvalTo treat anemia due to chronic kidney diseaseApprovedSEC 8-K Exhibit 99.1
March 27, 2024nda218408BAXComplete Response Letter—CRL issuedFDA Complete Response Letters
March 27, 2024Vemlidy (tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
March 29, 2024Voydeya (danicopan)AZNFDA approvalTo treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuriaApprovedFDA Novel Drug Approvals
March 29, 2024nda218224BAXComplete Response Letter—CRL issuedFDA Complete Response Letters
March 31, 2024Adcirca® (tadalafil)ONCOFDA approval—ApprovedSEC Form 10-Q

March 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Mar 2024Month disclosedNUPLAZID (pimavanserin)ACADTopline readoutnegative symptoms of schizophreniaNegativeSEC Form 10-K
Mar 2024Month disclosedzilebesiranALNYTopline readout—PositiveSEC Form 10-Q
Mar 2024Month disclosedreboxetine (AXS-12)AXSMTopline readout—PositiveSEC Form 10-Q
Mar 2024Month disclosed—IMRXTopline readout—PositiveSEC Form 10-Q
Mar 2024Month disclosedtambiciclib (SLS009)SLSTopline readout—Positivesec_424b
March 5, 2024—KRSAInterim readout—PositiveSEC 8-K Exhibit 99.1

March 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Mar 2024Month disclosedsovleplenib (HMPL-523)HCMTrial startwAIHA in ChinaCompletedSEC Form 10-K
Mar 2024Month discloseddeucrictibant (PHA121)PHVSTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedrezpegaldesleukin (NKTR-358)NKTRTrial startsevere-to-very severe alopecia areataCompletedSEC Form 10-Q
March 15, 2024HLP004HELPTrial startmoderate to severe GADCompletedSEC 8-K Exhibit 99.1
March 15, 2024CYB004HELPTrial startmoderate to severe GADCompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedenvometinibIMRXTrial startwith advanced solid tumors harboring RAF or RAS mutationsCompletedSEC Form 10-K
March 6, 2024IPH6501IPHATrial startRelapsed and/or Refractory CD20-expressing B-cell non-Hodgkin's lymphomaCompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedfirmonertinib (AST2818)AVBPTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedzelebrudomide (NX-2127)NRIXTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedPRX-115PLXTrial start—CompletedSEC Form 10-Q
Mar 2024Month disclosedVLA160124VALNTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedVLA160125VALNTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedVLA160126VALNTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2024Month disclosedVLA1601VALNTrial start—CompletedSEC Form 10-K

2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps March 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in March 2024?

4 PDUFA dates fell in March 2024: LCTX (Mar 2024), HETLIOZ® (March 4), MDGL (March 14), RCKT (March 31). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.